87 The Impact of Pre-Formed Donor-Specific HLA Antibodies on Early Clinical Outcomes in Lung Transplant Recipients
Fujimoto K, Shigemura N, Sareyyupoglu B, Bansal A, Minakata K, Shayan H, Ota T, Bhama J, Bonde P, Thacker J, Bermudez C, Zaldonis D, Zeevi A, Toyoda Y. 87 The Impact of Pre-Formed Donor-Specific HLA Antibodies on Early Clinical Outcomes in Lung Transplant Recipients. The Journal Of Heart And Lung Transplantation 2011, 30: s37. DOI: 10.1016/j.healun.2011.01.094.Peer-Reviewed Original ResearchPrimary graft dysfunctionMean fluorescent intensityAcute cellular rejectionEarly clinical outcomesClinical outcomesDSA groupDonor selectionSurvival rateDonor-specific HLA antibodiesClass II DSALung transplant recipientsPrimary graft failureLung transplant candidatesHLA-specific antibodiesLevels of AbsCellular rejectionGraft dysfunctionLTx candidatesLTx groupProspective crossmatchHLA antibodiesLung transplantTransplant recipientsDepletion therapyGraft failure43 Heart Transplantation in Sensitized Recipients, the Impact of Pre-Transplant Donor-Specific Antibodies on Clinical Outcome
Sareyyupoglu B, Toyoda Y, Fujimoto K, Teuteberg J, Shullo M, Zaldonis D, Bonde P, Bhama J, Bermudez C, Kormos R, Zeevi A. 43 Heart Transplantation in Sensitized Recipients, the Impact of Pre-Transplant Donor-Specific Antibodies on Clinical Outcome. The Journal Of Heart And Lung Transplantation 2011, 30: s21-s22. DOI: 10.1016/j.healun.2011.01.050.Peer-Reviewed Original Research